When involved in phase III drug evaluation studies, which responsibilities would the nurse have?
Monitor and observe clients closely for adverse effects
Work with animals which are given experimental drugs
Make decisions that will determine the effectiveness of the drug
Select appropriate clients to be involved in the drug study
The Correct Answer is A
a) Phase III clinical trials involve large groups of human participants and focus on confirming the drug's effectiveness and monitoring for adverse effects. The nurse plays a key role in observing and documenting any side effects experienced by the patients.
b) Working with animals is part of preclinical trials, not phase III studies. By the time a drug reaches phase III, it has already undergone animal testing.
c) While data collected in phase III trials contribute to determining a drug’s effectiveness, the decision-making is primarily done by researchers and regulatory agencies, not individual nurses.
d) Selection of appropriate clients for a drug study is generally determined by researchers and trial coordinators based on inclusion and exclusion criteria, rather than by nurses directly.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is C
Explanation
A. Complete blood count (CBC) and serum glucose levels are important for overall health monitoring but do not specifically assess drug metabolism or excretion, which are key factors in drug toxicity.
B. Pancreatic enzymes and urinalysis are useful for detecting pancreatic disorders and infections but are not primary indicators of drug toxicity.
C. Serum creatinine and liver function tests (LFTs) are critical for monitoring drug toxicity, especially in older adults. The kidneys and liver are responsible for drug metabolism and excretion. Impaired kidney function, indicated by elevated serum creatinine, can lead to drug accumulation and toxicity. Abnormal LFTs suggest liver dysfunction, which can affect drug metabolism and increase toxicity risk.
D. Serum lipids and electrolytes are important for cardiovascular and metabolic health but do not directly assess drug metabolism or toxicity risk.
Correct Answer is C
Explanation
A. While pediatric doses are often weight-based, this does not fully account for differences in drug metabolism and effects in children. Pediatric drug safety requires specific testing beyond weight comparisons to adults.
B. Relying on repeated use over time to determine safety is not an evidence-based approach. Drug approval for pediatric use requires formal clinical trials to establish safety and efficacy.
C. The U.S. FDA and other regulatory agencies require that drugs intended for pediatric use undergo clinical trials specifically designed to assess safety, efficacy, and appropriate dosing in children. This ensures that medications are appropriately tested before being marketed for pediatric patients.
D. While some post-marketing studies may include children, initial approval for pediatric use requires pre-market clinical testing. Relying solely on post-marketing studies does not ensure comprehensive safety data before widespread pediatric use.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.
